Clinical trials
Completed Phase 3 trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
11,053 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 167 |
| 2001 | 199 |
| 2002 | 285 |
| 2003 | 374 |
| 2004 | 479 |
| 2005 | 547 |
| 2006 | 596 |
| 2007 | 541 |
| 2008 | 595 |
| 2009 | 521 |
| 2010 | 511 |
| 2011 | 512 |
| 2012 | 500 |
| 2013 | 473 |
| 2014 | 480 |
| 2015 | 539 |
| 2016 | 451 |
| 2017 | 468 |
| 2018 | 484 |
| 2019 | 418 |
| 2020 | 372 |
| 2021 | 312 |
| 2022 | 273 |
| 2023 | 196 |
| 2024 | 108 |
| 2025 | 40 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11,053 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 318 |
| AstraZeneca | 278 |
| Pfizer | 275 |
| Novartis Pharmaceuticals | 272 |
| Eli Lilly and Company | 270 |
| Sanofi | 212 |
| Hoffmann-La Roche | 202 |
| Novo Nordisk A/S | 176 |
| Boehringer Ingelheim | 153 |
| Bristol-Myers Squibb | 152 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 466 |
| HIV Infections | 266 |
| Diabetes Mellitus | 253 |
| Breast Neoplasms | 238 |
| Pain | 238 |
| Asthma | 200 |
| Pulmonary Disease, Chronic Obstructive | 188 |
| Major Depressive Disorder | 178 |
| Hypertension | 163 |
| Carcinoma, Non-Small-Cell Lung | 151 |
Trials
Showing 1 to 25 of 11,053. Each trial links to its page on Pharma Observatory.
10,953 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.